Phase II · Clinical Validation
We replace subjective pathology with pixel-level biomarker quantification — delivered the same day, from a single biopsy.
Precision enzymatic micro-dissection liberates extracellular vesicles directly from the tumor microenvironment — preserving native cargo and bypassing blood-borne contamination.
Proprietary laminar-flow cartridges isolate lipid-bilayer vesicles in the 30–150 nm range with greater than 95% purity — physical principle, not affinity, drives the cut.
Concurrent multiplex of HER2, ER/PR, PD-L1 and Ki-67 — quantified, not estimated. The clinical signal becomes a number, not an interpretation.
Conventional pathology is subjective, slow, and observer-dependent. We replace it with deterministic, AI-driven, pixel-level biomarker quantification — delivered same day.
Manual interpretation introduces variance in early-stage histological review, where sub-visual expressions can be missed entirely.
AI models detect sub-visual expressions missed in 22% of early-stage histological reviews — measured, not interpreted.
A network of clinical and research partners walks the platform from biopsy to patient cohort — building the evidence substrate behind every quantified readout.
Deep collaboration on proteomic profiling and multi-omic data integration — building the analytical substrate that lets the platform read sub-visual biomarker expression at the earliest disease stage.
Direct access to clinical patient cohorts for real-world evidence and diagnostic sensitivity validation — comparing extracellular-vesicle signatures against standard immunohistochemistry across a 300-patient breast-cancer study.
A proprietary, three-step pathway isolates extracellular vesicles directly from biopsy tissue — preserving lipid-bilayer integrity and protein cargo for multiplexed readout.
Receptor tyrosine-protein kinase erbB-2. Therapy stratification.
Hormone receptor expression for endocrine pathway response.
Programmed death-ligand 1. Immunotherapy candidate triage.
Proliferation index for tumor severity grading.
Improvement in biomarker expression accuracy versus qualitative review — measured against IHC reference panels.
End-to-end reporting versus 21–28 days for traditional histology — without sacrificing fidelity.
Reduction in clinical exam overhead through automation of the quantification pipeline.
OncoGenix collapses ten days of legacy reporting into a single-day result — a step-change in operational velocity that reshapes the clinical decision window.
Extracellular vesicle technology is the substrate for an integrated, multi-cancer precision-oncology platform — built on quantifiable signal, not interpretation.
EV signatures enable sensitive, non-invasive tumor detection at the earliest stage of disease.
Comprehensive EV cargo reveals tumor subtype and the specific genetic drivers behind it.
Match therapies to patient-specific EV biomarkers for optimized clinical outcomes.
Integrated EV platforms drive adaptive, predictive oncology care — at scale.